Large And Small, These Biotech Stocks Could Be Big Winners
One large-cap biotech and two small-cap biotechs – one which “has been content with staying out of the limelight” and a second, higher-risk play –…
On the Radar Reports
A “Treasure Hunt” Options Play As Retail Reopens
As the retail business highlighted in today’s article has reopened, “Customers have been braving public spaces in droves to visit its brick-and-mortar locations and tear…
Bored Retail Traders’ Journey Into “All Manner Of Wall Street Exotica” – And Why It’ll End Badly
Bored from staying at home, and lured by free trading, individual investors are engaging in some new – and perhaps ill-advised – activities in the…
7 “Bright Spot” Biotech Stocks In The Spotlight
“With the scramble for viral and antibody testing kits, and the ultimate goal of finding a vaccine for Covid-19, many biotech companies are suddenly in…
3 “Compelling, But Affordable” Biotech Names For A Bullish View Of The Market
In a bullish take on current circumstances, Morgan Stanley’s head of U.S. equity strategy argued in a recent note to clients that the current state…
3 Top Stock Picks From The “Recession-Proof” Biotech Sector
It should come as no surprise that one of the top biotech stocks to consider right now, as identified by the author of today’s article,…
Why This Seemingly ‘Great Deal’ Pharma Stock Is Contraindicated
With a massive cash balance (and no debt), rapidly growing revenue and earnings, and a well-stocked pipeline, the pharma stock that’s the focus of today’s…
3 Under-$4 Biotech Stocks With Massive Growth Prospects
While the broader market has been all over the place over the past few months, one area that has performed significantly better than the S&P…
3 “Exciting Biotech Plays That Won’t Break The Bank”
Looking for “exciting biotech plays that won’t break the bank”? Today’s article highlights three such plays, all of which are trading under $3 per share,…
Why This Biotech’s Mixed Clinical Results Shouldn’t Discourage Investors With A High Risk Tolerance
The small-cap biotech highlighted in today’s article has had mixed clinical results when it comes to one of its novel cancer immunotherapy candidates. The author,…